英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

undulatory    
a. 波动的,起伏的,起浪的

波动的,起伏的,起浪的

undulatory
adj 1: resembling waves in form or outline or motion [synonym:
{undulatory}, {undulant}]

Undulatory \Un"du*la*to*ry\ (?; 277), a. [Cf. F. ondulatoire.]
Moving in the manner of undulations, or waves; resembling the
motion of waves, which successively rise or swell rise or
swell and fall; pertaining to a propagated alternating
motion, similar to that of waves.
[1913 Webster]

{Undulatory theory}, or {Wave theory} (of light) (Opt.), that
theory which regards the various phenomena of light as due
to undulations in an ethereal medium, propagated from the
radiant with immense, but measurable, velocities, and
producing different impressions on the retina according to
their amplitude and frequency, the sensation of brightness
depending on the former, that of color on the latter. The
undulations are supposed to take place, not in the
direction of propagation, as in the air waves constituting
sound, but transversely, and the various phenomena of
refraction, polarization, interference, etc., are
attributable to the different affections of these
undulations in different circumstances of propagation. It
is computed that the frequency of the undulations
corresponding to the several colors of the spectrum ranges
from 458 millions of millions per second for the extreme
red ray, to 727 millions of millions for the extreme
violet, and their lengths for the same colors, from the
thirty-eight thousandth to the sixty thousandth part of an
inch. The theory of ethereal undulations is applicable not
only to the phenomena of light, but also to those of heat.
[1913 Webster]


请选择你想看的字典辞典:
单词字典翻译
Undulatory查看 Undulatory 在百度字典中的解释百度英翻中〔查看〕
Undulatory查看 Undulatory 在Google字典中的解释Google英翻中〔查看〕
Undulatory查看 Undulatory 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC)
  • FDA Approves Cemiplimab as Adjuvant Immunotherapy for High . . .
    Last week, Regeneron announced the U S Food and Drug Administration (FDA) approval of cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC), particularly in those with a high risk of recurrence after surgery and radiation 1 The PD-1 inhibitor was evaluated under priority review
  • Behind the FDA Approval: Adjuvant Cemiplimab Shifts Treatment . . .
    Vishal A Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence
  • Cemiplimab Becomes First Treatment Approved for Advanced . . .
    This approval, the first for cemiplimab, a checkpoint immunotherapy that targets the PD-1 pathway, is also the first option to be approved for patients with advanced forms of CSCC, the second most common skin cancer in the U S and the deadliest non-melanoma skin cancer
  • FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment . . .
    FDA approved of Regeneron Pharmaceutical’s Libtayo (cemiplimab-rwlc)as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at an increased risk of recurrence following surgery and radiation 1 Libtayo was reviewed by FDA under Priority Review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of
  • 2025 FDA added indications to dermatologic medications
    In October 2025, the FDA approved Libtayo (cemiplimab) as a treatment for cutaneous squamous cell carcinoma that has a high risk of recurring after it has been treated with surgery and radiation
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions An additional regulatory application is also under review in the European Union, with a decision expected by the first half of 2026
  • FDA Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell . . .
    The FDA has approved cemiplimab-rwlc (Libtayo) for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation 1
  • FDA Approvals in Oncology: October-December 2025
    Cemiplimab (Libtayo) was approved for use after surgery and adjuvant radiation in patients whose cutaneous squamous cell carcinoma (CSCC)—one of the most common forms of skin cancer—has a high risk of recurring





中文字典-英文字典  2005-2009